Is Ktra a good buy

**Kintara Therapeutics (KTRA) does not appear to be a good buy at this time.** Here's why: 1. **Financial Ratios**: KTRA's P/E ratio is negative, indicating that the company is not profitable as the EPS is negative. The P/B ratio is also negative, suggesting that the stock is trading below its book value. A negative P/S ratio further indicates that the market is not valuing the company's sales effectively. 2. **Technical Indicators**: The stock's 50-day moving average is $0.24, while the 5-day and 10-day moving averages are $0.19 and $0.21, respectively. This indicates a downward trend in the stock price, which is a negative sign. 3. **Market Sentiment**: There is a bearish sentiment in the market, as evidenced by the stock's 52-week range being between $0.08 and $4.92, with a recent close of $0.19. The stock has also experienced a significant drop, with a 1-year price target of $14.00, which is a long way from the current price. 4. **Strategic Developments**: Despite strategic collaborations, such as with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China, the company's financials raise concerns. In conclusion, KTRA's negative financial ratios, downward trending technical indicators, and bearish market sentiment suggest that it is not a good buy at this time.